Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZGene)Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZGene)<;Peter A. Csurhes;Michael P. Pender;Pamela A. McCombe" /> 期刊论文

期刊论文详细信息
International Journal of Molecular Sciences
Interleukin-6 Gene Promoter-572 C Allele may Play a Role in Rate of Disease Progression in Multiple Sclerosis
Jun Yan3  Jia Liu3  Clement Yihao Lin3  rib-type="author">Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZGene)Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZGene)<1  Peter A. Csurhes3  Michael P. Pender2  Pamela A. McCombe3 
[1] School of Medicine, The University of Queensland, and Department of Neurology, Royal Brisbane & Women’s Hospital, 4029 Brisbane, Australia; E-Mail:;The University of Queensland, Centre for Clinical Research, Royal Brisbane & Women’s Hospital, 4029 Brisbane, Australia; E-Mails:
关键词: multiple sclerosis;    Interleukin-6;    polymorphism;    allele;    genotype;    disease progression;   
DOI  :  10.3390/ijms131013667
来源: mdpi
PDF
【 摘 要 】

Multiple sclerosis (MS) is an inflammatory demyelinating disease affecting the central nervous system. Although the exact pathogenesis of MS is unknown, it is generally considered to be an autoimmune disease, with numerous genetic and environmental factors determining disease susceptibility and severity. One important mediator of immune responses and inflammation is interleukin-6 (IL-6). Previously, elevated levels of IL-6 in mononuclear cells in blood and in brain tissue from MS patients have been reported. Various polymorphisms in the promoter region of the IL6 gene have also been linked with IL-6 protein levels. In MS, several small studies have investigated whether two IL6 promoter polymorphisms (−597 G>A and −174 G>C) correlate with MS susceptibility, but with varying results. In the present study, we analyzed these polymorphisms, together with an additional polymorphism (−572 G>C) in 279 healthy controls and 509 patients with MS. We found no significant differences between MS patients and healthy controls for the different −597 or −174 IL6 promoter alleles or genotypes. There was a slight reduction in the percentage of individuals with MS who carried a C allele at position −572, although this was not significant after correction for multiple comparisons. Interestingly, however, the −572 C allele showed a significant correlation with the MS severity score, suggesting a possible role in disease progression.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.

【 预 览 】
附件列表
Files Size Format View
RO202003190041147ZK.pdf 676KB PDF download
  文献评价指标  
  下载次数:9次 浏览次数:23次